ILMN Overview

Illumina, Inc. is engaged in providing sequencing-and array-based solutions for genetic and genomic analysis. Its products and services serve customers in a range of markets, enabling the adoption of genomic solutions in research and clinical settings. Its DNA sequencing technology is based on its reversible terminator-based sequencing chemistry, referred to as sequencing by synthesis biochemistry. Its BeadArray technology combines microscopic beads and a substrate in a manufacturing process to produce arrays that can perform many assays simultaneously. Its sequencing applications include whole-genome sequencing kits, which sequence entire genomes of any size and complexity, and targeted resequencing kits, which can sequence exomes, specific genes, RNA or other genomic regions of interest. Its customers include genomic research centers, academic institutions, government laboratories, hospitals, pharmaceutical, biotechnology, commercial molecular diagnostic laboratories, and others.

Wall Street analysts forecast ILMN stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ILMN is133.54 USD with a low forecast of 40.50 USD and a high forecast of 170.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Illumina Inc revenue for the last quarter amounts to 1.16B USD, increased 4.98

Illumina Inc. EPS for the last quarter amounts to 2.18 USD, increased 84.75

Illumina Inc (ILMN) has 8600 emplpoyees as of March 10 2026.

Today ILMN has the market capitalization of 19.00B USD.